AMGN
Amgen Inc.NasdaqResearch view
$414.61+2.11%
Sep 25 close · 1D EOD · Databento
HealthcareBiological Products, (No Diagnostic Substances)Mega-capSEC EDGAR FY 2025-12-31
The numbers · FY2025, filed
SEC EDGARMarket cap$224.2B
Revenue$36.8B+10.00%
Net income$7.7B
EPS, diluted$14.23+88.20%
Operating margin24.7%
Return on equity89.1%
All filed figures
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Market Cap$224.2B
Enterprise Value$274.2B
Income$7.7B
Sales$36.8B
Book/sh$16.01
Cash/sh$16.89
Dividend TTM$9.66
Payout67%
Employees—
IPO—
Quick Ratio0.90
Current Ratio1.14
Debt/Eq6.84
EPS (ttm)$14.23
EPS this Y88.2%
EPS past 3/5Y5.5%
Sales past 3/5Y11.8%
EPS Y/Y TTM88.2%
Sales Y/Y TTM10.0%
Shs Outstand540.63M
ROA8.5%
ROE89.1%
ROIC13.3%
Gross Margin—
Oper. Margin24.7%
Profit Margin21.0%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue by fiscal year
$26.0B
FY21
$26.3B
FY22
$28.2B
FY23
$33.4B
FY24
$36.8B
FY25
Operating leverage — margins
GrossOperatingNet
Financials, annual · income and cash flowSEC EDGAR · open ▸
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $7.6B | $9.6B | $7.9B | $7.3B | $9.1B |
| Net Income | $5.9B | $6.6B | $6.7B | $4.1B | $7.7B |
| Diluted EPS | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
| Operating Cash Flow | $9.3B | $9.7B | $8.5B | $11.5B | $10.0B |
| Free Cash Flow | $8.4B | $8.8B | $7.4B | $10.4B | $8.1B |
Same industry
In the screener →Follow the news. Track the move.
AMGN story timeline
Company updates and connected market context, with the dated price move attached.
2
Stories
0
Direct
Sector context/Earnings
Amgen and AstraZeneca report positive lung cancer trial results
Amgen and AstraZeneca reported positive results from a lung-cancer trial. The immediate setup is therefore event-driven but unquantified, with the commercial significance for AMGN and AZN still unproven.
Price history unavailable
Investing.com · 18d ago
View both sides →Sector context/Earnings
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
Disappointing clinical-trial results are weighing on Novartis, Amgen and the Dow in Tuesday trading. With no trial readout details disclosed in the report, the immediate setup is a sentiment hit whose effect on Amgen’s earnings outlook remains unquantified.
Price history unavailable
Yahoo Finance · 18d ago
View both sides →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.